gsk201410296k.htm
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For period ending October 2014
GlaxoSmithKline plc
(Name of registrant)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F
Form 20-F x Form 40-F
--
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.
Yes No x
--
GlaxoSmithKline plc
Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons
In accordance with DTR 3.1.4R(1)(a) I give details of changes in the interests of Mr S Dingemans, a Director, in the Ordinary Shares of GlaxoSmithKline plc (the "Company") arising from the grant of 238 Share options over Ordinary Shares, at an option price of £11.31 per share, pursuant to the GlaxoSmithKline plc ShareSave Plan 2012, on 29 October 2014.
The Company was advised of the transaction on 29 October 2014.
V A Whyte
Company Secretary
29 October 2014
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
GlaxoSmithKline plc
(Registrant)
Date: October 29, 2014
By: VICTORIA WHYTE
----------------------
Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc